PLIVA, Inc. v. Mensing

2011-06-23

Headline: Federal drug rules pre-empt state warning lawsuits against generic manufacturers, blocking many failure-to-warn claims and leaving patients who received generics with fewer state-law remedies.

Holding: The Court held that federal drug statutes and FDA regulations requiring generic labels to match brand-name labels pre-empt state-law failure-to-warn claims because generics could not independently provide stronger warnings.

Real World Impact:

Prevents many state failure-to-warn lawsuits against generic drug makers.
Leaves injured patients often without state-law remedies after receiving generics.
Makes label changes depend on FDA and brand-name manufacturers, not individual generics.

Topics: drug safety, generic drugs, warning labels, FDA rules, patient lawsuits

Summary

Background

Two women, Gladys Mensing and Julie Demahy, took generic metoclopramide and later developed a serious movement disorder called tardive dyskinesia. They sued the makers of the generic drugs under Minnesota and Louisiana law, saying the manufacturers failed to provide adequate warning labels. The generic drugs copied the brand-name drug Reglan, and the cases were consolidated after the Courts of Appeals upheld the state-law claims.

Reasoning

The Court asked whether federal drug law and FDA rules conflict with state tort duties to provide adequate warnings. The majority found that federal law requires generic labels to match brand-name labels and, as interpreted by the FDA, prevents generic makers from unilaterally strengthening warnings. The Court deferred to the FDA’s reading that the usual label-change methods (the CBE process and “Dear Doctor” letters) were not available to generics. Because generics could not independently change labels, the Court concluded it was impossible to obey both federal rules and state-law duties, so the state claims are pre-empted.

Real world impact

The decision reverses the Fifth and Eighth Circuit rulings and remands the cases, effectively barring many state failure-to-warn lawsuits against generic manufacturers when the label at issue must match a brand-name label. Injured patients who received generics may be left without a state-law remedy, and safety changes must proceed through the FDA and the brand-name manufacturer.

Dissents or concurrances

Justice Sotomayor (joined by three Justices) dissented, arguing the majority weakens the demanding standard for impossibility pre-emption and that generics could have sought FDA action, so pre-emption should not be decided categorically here.